LITHOBID (lithium carbonate) by ANI Pharmaceuticals is 12. First approved in 1979.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
LITHOBID (lithium carbonate) is an oral extended-release tablet used as a mood stabilizer for bipolar disorder. The exact mechanism of action remains unknown, but lithium is completely absorbed from the gastrointestinal tract with peak levels occurring 2-6 hours post-dose. It is not metabolized and is primarily eliminated unchanged in urine with an elimination half-life of 18-36 hours.
Approaching loss of exclusivity with minimal recent commercial activity signals a mature, stable product with limited growth opportunities and likely smaller dedicated team.
12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T max ) occur 0.25 to 3 hours…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects
Worked on LITHOBID at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on LITHOBID offers stable, established expertise in psychiatry and mood disorder management but limited growth and innovation opportunities. The approaching LOE and minimal linked job count suggest this role is suitable for candidates seeking maintenance of a mature product rather than career acceleration.